Aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator ) with affinity to PPARα and PPARγ, which was under development by Hoffmann–La Roche for the treatment of type II diabetes. It is no longer in phase III clinical trials.

CAS：475479-34-6
中文别名：(S)-2-甲氧基-3-[4-[2-(5-甲基-2-苯基恶唑-4-基)乙氧基]苯并[B]噻吩-7-基]丙酸;
英文别名：UNII-41T4OAG59U;R-1439;(2S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl]propanoic acid;
分子式：C24H23NO5S
分子量：437.508
精确质量：437.13
Psa：110.03
Logp：5.1283

密度：1.29
沸点：665.151ºC at 760 mmHg
闪点：356.071ºC
折射率：1.627